- Home
- CASI vs HXHX Comparison
CASI vs HXHX Comparison
Compare CASI & HXHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- HXHX
- Stock Information
- Founded
- CASI 1991
- HXHX 2003
- Country
- CASI China
- HXHX China
- Employees
- CASI N/A
- HXHX N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- HXHX Trucking Freight/Courier Services
- Sector
- CASI Health Care
- HXHX Industrials
- Exchange
- CASI Nasdaq
- HXHX Nasdaq
- Market Cap
- CASI 31.0M
- HXHX 36.9M
- IPO Year
- CASI 1996
- HXHX 2025
- Fundamental
- Price
- CASI $1.89
- HXHX $1.64
- Analyst Decision
- CASI Strong Buy
- HXHX
- Analyst Count
- CASI 1
- HXHX 0
- Target Price
- CASI $4.00
- HXHX N/A
- AVG Volume (30 Days)
- CASI 8.4K
- HXHX 907.0K
- Earning Date
- CASI 05-20-2025
- HXHX 01-01-0001
- Dividend Yield
- CASI N/A
- HXHX N/A
- EPS Growth
- CASI N/A
- HXHX N/A
- EPS
- CASI N/A
- HXHX 0.26
- Revenue
- CASI $28,537,000.00
- HXHX $25,571,810.00
- Revenue This Year
- CASI N/A
- HXHX N/A
- Revenue Next Year
- CASI N/A
- HXHX N/A
- P/E Ratio
- CASI N/A
- HXHX $5.97
- Revenue Growth
- CASI N/A
- HXHX N/A
- 52 Week Low
- CASI $1.64
- HXHX $1.35
- 52 Week High
- CASI $7.67
- HXHX $6.29
- Technical
- Relative Strength Index (RSI)
- CASI 44.54
- HXHX N/A
- Support Level
- CASI $1.64
- HXHX N/A
- Resistance Level
- CASI $1.94
- HXHX N/A
- Average True Range (ATR)
- CASI 0.09
- HXHX 0.00
- MACD
- CASI -0.00
- HXHX 0.00
- Stochastic Oscillator
- CASI 55.77
- HXHX 0.00
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.